|UK Students, EU Students, International Students
|8th December 2023
|12th January 2024
The AIM (Advanced Inter-Disciplinary Models) DTP is funded by the MRC between three Partners – the Universities of Birmingham, Leicester and Nottingham – and three more Associate Partners – the Research Complex at Harwell, Mary Lyon Centre and Rosalind Franklin Institute. We have a range of exciting and diverse PhD 4-year projects at all 3 partner Institutions which are now open for a September 2024 start and those available at The University of Nottingham are detailed below.
Projects with an industry partner (iCASE projects) offer a unique opportunity to undertake translational research and come with a mandatory placement requirement and an enhanced stipend.
Full information about funding of these projects and application details, including application form plus Equality, diversity and inclusion form are available at https://more.bham.ac.uk/mrc-aim/phd-opportunities/.
The deadline for submitting applications is 12.00 am GMT, Friday, 12 January 2024. Interviews will take place during the week commencing 26 February and will be held via Zoom.
Applicants must hold, or be about to obtain, a First or Upper Second class UK honours degree, or the equivalent qualifications gained outside the UK, in a relevant subject. A master’s qualification in a related area could be beneficial, as could additional relevant research experience.
Projects open for application
School of Chemistry
Project Title Mechanism of Action Directed Implementation of a High Activity Anti-Pancreatic Cancer Lead
Supervisors: Simon Woodward, email@example.com
Dr Isolda Romero-Canelón (UoB), Dr Huw Williams (UoN)
A 4-year PhD studentship is currently available in a Chemistry-Pharmacy-Bioscience team coordinated by Simon Woodward, Huw Williams and Isolda Romero-Canelón to be filled as soon as possible, for an October 2024 start.
The student will be based in both the Universities of Nottingham and Birmingham and involved in research leading to a multidisciplinary PhD involving the optimisation and understanding of a unique anti-pancreatic cancer pro-drug.
Recently, we have discovered a new and unusual titanium-based compound that shows dramatic activity against therapeutically highly challenging pancreatic cancer cell lines (link1, link2). Preliminary evidence suggests our compound achieves this by a complex cell signalling process. This MRC-backed PhD will untangle how this is achieved, giving the candidate exceptional skills in medicinal chemistry, cancer biology and ultra-high field multi-nuclear biological NMR in a new and exciting area.
Training will alternate between Birmingham and Nottingham leading to skills in practical chemistry and biology, advanced instrumentation and theory.
The successful candidate will come from a background in chemistry, pharmacy, bioscience or medicine and will be curious to explore new avenues in cancer biology and advance unusual agents towards their use in the clinic.
Type / Role: